Author: Peggy O’Hare | Category: In The News | Biology of Aging | Biology of Aging | April 06, 2016
Professors Randy Strong and Z. Dave Sharp, researchers at the Barshop Institute of Longevity and Aging,.were featured in the San Antonio Business Journal for their new and improved version of the drug rapamycin.
Rapamycin, a drug derived from microbes discovered in the early 1970s in the soils of Easter Island in the South Pacific, was proven to be the first pharmaceutical capable of prolonging the life spans of older mice, according to research done in San Antonio.
Made in laboratory settings today, rapamycin has long been used by transplant patients to help fight organ rejection. It’s also used in heart stents to prevent clots from forming in vessels and to treat certain cancers.
Rapamycin Holdings CEO Randy Goldsmith explained that the formula known as eRapa is “an anti-aging intervention.”
The eRapa formula has the potential to slow the progression of some age-related diseases like Alzheimer’s and to prevent certain genetically inherited cancers, according to the researchers.
“We’re in that great place where anything’s possible,” Strong said of eRapa in the article.
To see the full article, click here.
Copyright © 2018 The University of Texas Health Science Center at San Antonio
Links provided from the UTHSCSA pages to other websites do not constitute or imply an endorsement of those sites, their content, or products and services associated with those sites.